Description
A prodrug form of VRT-043198; inhibits LPS-induced increases in serum IL-1β levels in mice at 50, 100, and 200 mg/kg; reduces oxazolone-induced ear edema and levels of IL-1β, IL-18, and IFN-γ in ear tissue in an oxazolone-sensitized mouse model of delayed-type hypersensitivity; reduces forepaw inflammation in a mouse model of collagen-induced arthritis in a dose-dependent manner; decreases seizure duration and the number of seizures in a mouse model of acute seizures induced by hippocampal kainic acid injection at ≥50 mg/kg, as well as delays the onset of seizures at 100 and 200 mg/kg; reduces the aggregated duration of epileptic activity in a mouse model of chronic epilepsy
Formal name: N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]-L-prolinamide
Synonyms: Belnacasan
Molecular weight: 509
CAS: 273404-37-8
Purity: ≥98%
Formulation: A crystalline solid
